Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-β1b-treated multiple sclerosis patients
Authors:
- 1 June 1998
- journal article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 4 (3) , 174-177
Abstract
To identify immunological markers that could be used to monitor relapsing-remitting multiple sclerosis (RRMS) course/activity during interferon beta 1b (IFNβ1b) therapy, we longitudinally studied HLA-DR and CD25 expression by T lymphocytes in 15 IFNβ1b-treated RRMS patients. Peripheral blood T cell subsets were analysed before therapy (T0), and after 1 (T1), 2 (T2), 3 (T3), 6 (T4) and 12 (T5) months after therapy initiation. HLADR expression and the CD3+HLA-DR+ T cell number showed a peculiar trend in almost all (14/15) the patients: a significant decrease at T1 and T2 followed by a return to pre-treatment levels from T3 to T5. At T1 and T2, eight patients showed an up-regulation of CD25 on CD4, as well as an increase in the CD4+CD25+ cell number. However, a marked, significant reduction of this T cell subset was observed in all the patients at T3, followed by the progressive return to pre-treatment values from T4 to T5. All the patients developed anti-IFNβ1b `binding' antibodies within the first three months of therapy. Our findings demonstrate that: (1) the expression of HLA-DR and CD25 on T cells, as well as the number of circulating CD3+HLA-DR+ and CD4+CD25+ cells, are only transiently reduced in vivo in IFNβ1b-treated RRMS patients, (2) the expression of HLA-DR and CD25 on T lymphocytes cannot be used to monitor MS course/activity during IFNβ1b therapy, (3) the long-lasting beneficial effect of IFNβ1b on RRMS reported in the literature cannot be explained by the down-regulation of MHC class II antigens and/or interleukin-2 receptor expression induced by this cytokine.Keywords
This publication has 15 references indexed in Scilit:
- Interferon beta‐1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosisAnnals of Neurology, 1996
- Interferon-beta sub 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosisNeurology, 1996
- The interferons: Biological effects, mechanisms of action, and use in multiple sclerosisAnnals of Neurology, 1995
- A Brief History of the Use of Interferons as Treatment of Multiple SclerosisArchives of Neurology, 1994
- In vitro and in vivo inhibition of mitogen‐driven T‐cell activation by recombinant interferon betaNeurology, 1993
- Interferon β decreases T cell activation and interferon γ production in multiple sclerosisJournal of Neuroimmunology, 1993
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993
- Contrasting effect of alpha/beta- and gamma-interferons on expression of macrophage Ia antigens.Journal of Experimental Medicine, 1986
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983